UBS Sees Strong Sales Outlook for Eli Lilly’s Zepbound and Mounjaro

Eli Lilly & Company (NYSE:LLY) ranks among the best set-it-and-forget-it stocks to buy. On June 27, UBS kept its Buy rating and $1,050 price target on Eli Lilly & Company (NYSE:LLY), pointing to the pharmaceutical company’s dominant position in the market for treating obesity.

UBS Sees Strong Sales Outlook for Eli Lilly’s Zepbound and Mounjaro

Pixabay/Public Domain

Sales estimates for Eli Lilly & Company (NYSE:LLY)’s weight-loss treatment Zepbound may surpass market expectations by about 15%, according to the investment bank’s analysis, while estimates for the diabetes prescription Mounjaro are in line with current market projections. In general, UBS expects Eli Lilly’s quarterly sales to exceed expectations by 2%.

According to UBS, the company’s next major driver is the SURPASS cardiovascular outcomes trial. The bank added that Eli Lilly & Company (NYSE:LLY)’s second-quarter earnings would briefly benefit from CVS Health’s formulary shift.

Eli Lilly & Company (NYSE:LLY) is a major global pharmaceutical company that develops, manufactures, and distributes a wide range of drugs. Founded in 1876, it has grown to become one of the world’s largest pharmaceutical companies.

While we acknowledge the potential of LLY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

Read More: 10 Best Magic Formula Stocks for 2025 and 10 Best Retirement Stocks to Buy According to Hedge Funds

Disclosure: None.